Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mevidalen (LY3154207) in Healthy Subjects and Parkinson's Disease
NCT02562768Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing Mevidalen with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug Administration at Day 15. Started Sep 2015; status: completed.
02
Drugs
mevidalen
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02562768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02562768.